Cannabinoid receptor antagonists: Pharmacological opportunities, clinical experience, and translational prognosis

Expert Opinion on Emerging Drugs

Volumn 14, Issue 1, 2009, Pages 43-65

  Janero, David R ^a   Makriyannis, Alexandros ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

2 arachidonoylglycerol; Addiction; AM4113; Anandamide; Clinical trial; Diabetes; Drugs; Endocannabinoid; G protein coupled receptor; Immunomodulation; Inflammation; Insulin resistance; Ligands; Metabolic syndrome; Neutral antagonist; Obesity; Overweight; Pain; Rimonabant; Steatosis; Substance abuse; Taranabant; Translational biomedicine

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ALLI; AM 4113; AMFEPRAMONE; AVE 1625; BENZPHETAMINE; BMS 646256; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CP 945598; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; HYDRIN; IBIPINABANT; MAZINDOL; METHAMPHETAMINE; OTENABANT; PHENDIMETRAZINE TARTRATE; PHENMETRAZINE; PHENTERMINE RESIN; PYRAZOLE DERIVATIVE; RIMONABANT; ROSONABANT; SIBUTRAMINE; SURINABANT; TARANABANT; TETRAHYDROLIPSTATIN; TM 38837; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 24343;

AGGRESSION; ANTIINFLAMMATORY ACTIVITY; ANXIETY; ATHEROMA; BARIATRIC SURGERY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DEPENDENCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; FOOD INTAKE; GLYCEMIC CONTROL; HEART RATE; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFLAMMATION; INSOMNIA; LIFESTYLE; LIGAND BINDING; LIPID STORAGE; LIPOPHILICITY; MENTAL DISEASE; METABOLIC DISORDER; NAUSEA; NEUROTRANSMISSION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUBSTANCE ABUSE; SUICIDAL IDEATION; TACHYCARDIA; UNITED STATES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; METABOLISM;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENDOCANNABINOIDS; HUMANS; OBESITY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION;

EID: 65649122618     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210902736568     Document Type: Review

References (183)

1. Fattore L, Fadda P, Spano MS, et al. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol 2008;286:S97-S107
2. Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 2008;20:1-9 •• Up-to-date overview of endocannabinoid biochemistry.
3. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol 2008;20:10-14 •• Up-to-date overview of cannabinoid receptors.
4. Pertwee RG. The pharmacology of canabinoid receptors and their ligands: an overview. Int J Obes 2006;30:S13-8
5. Mackie K. Signaling via CNS cannabinoid receptors. Mol Cell Endocrinol 2008;286:S60-5
6. Ghasemi M, Sadeghipour H, Dehpour AR. Anandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: involvement of cannabinoid CB1 and vanilloid VR1 receptors. BJU Int 2007;100:1385-1390 (Pubitemid 350043915)
7. Oz M. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol Ther 2006;111:114-144 (Pubitemid 43786201)
8. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007;152:567-575 (Pubitemid 350041541)
9. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008;160:1-24 •• Contemporary review of enzymes that help regulate endocannabinoid tone.
10. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007;14:1347-1356 (Pubitemid 350257008)
11. Fowler CJ. The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol 2007;152:594-601 (Pubitemid 350034968)
12. Marnett LJ. Decoding endocannabinoid signaling. Nat Chem Biol 2008;5:8-9
13. Long JZ, Li W, Booker L, et al. Selective blockade of 2-arachidonoylglyerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2008;5:37-44
14. Vemuri KV, Janero DR, Makryannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: Drugs for obesity and the metabolic syndrome. Physiol Behav 2008;93:671-686
15. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007;18:129-140 (Pubitemid 46412082)
16. Janero DR, Makriyannis A. Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity. Curr Psychiatry Rep 2007;9:365-373 (Pubitemid 47559357)
17. Vandevoorde S. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem 2008;8:247-267 (Pubitemid 351795772)
18. Pavlopoulos S, Thakur GA, Nikas SP, et al. Cannabinoid receptors as therapeutic targets. Curr Pharm Des 2006;12:1751-1769
19. Pei Y, Mercier RW, Anday JK, et al. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol 2008;15:1207-1219
20. Ibrahim MM, Deng H, Zvonok A, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003;100:10529-10533 (Pubitemid 37071912)
21. Ross RA. Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor. Br J Pharmacol 2007;152:565-566 (Pubitemid 350034967)
22. Scheen AJ. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO program with rimonabant. J Neuroendocrinol 2008;20 (Suppl 1):139-46 •• Comprehensive discussion of the data from the rimonabant RIO trials and their implications.
23. Cohen DA. Neurophysiological pathways to obesity: below awareness and beyond individual control. Diabetes 2008;57:1768-1773
24. Wisse BE, Kim F, Schwartz MW. An integrative view of obesity. Science 2007;318:928-929
25. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008;263:336-352 (Pubitemid 351342683)
26. Jolliffe D. Extent of overweight among US children and adolescents from 1971 to 2000. Int J Obes Relat Metab Disord 2004;28:4-9
27. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555
28. World Health Organization. Obesity and overweight. 2006. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html
29. International Obesity TaskForce. IOTF prevalence data. 2008. Available from: http://www.iotf.org/database/
30. Corica F, Corsonello A, Apalone G, et al. Metabolic syndrome, psychological status and quality of life in obesity: the QUOVADIS study. Int J Obesity 2008;32:185-191
31. Perrini S, Leonardini A, Laviola L, et al. Biological specificity of visceral adipose tissue and therapeutic intervention. Arch Physiol Biochem 2008;114:277-286
32. Fernandez ML. The metabolic syndrome. Nutr Rev 2007;65:S30-4
33. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007;17:319-326 (Pubitemid 46551691)
34. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004;27:2444-2449 (Pubitemid 39281399)
35. Wang Y, Beydoun MA. The obesity epidemic in the United States: gender, age, socioeconomic, racial/ethnic, and geographic characteristics. A systematic review and meta-regression analysis. Epidemiol Rev 2007;29:6-28
36. Sullivan PW, Ghushchyan V, Wyatt HR, et al. The medical cost of cardiometabolic risk factor clusters in the United States. Obesity 2007;15:3150-3158 (Pubitemid 351256679)
37. Jones LR, Wilson CI, Wadden TA. Lifestyle modification in the treatment of obesity: an educational challenge and opportunity. Clin Pharmacol Ther 2007;81:776-779 (Pubitemid 46625116)
38. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75
39. Hoerger TJ, Ahmann AJ. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes. J Manag Care Pharm 2008;14:S2-14 (Pubitemid 351325189)
40. Bult MJ, van Dalen T, Muller AF .Surgical treatment of obesity. Eur J Endocrinol 2008;158:135-145
41. Abell TL, Minocha A. Gastrointestinal complications of bariatric surgery: diagnosis and therapy. Am J Med Sci 2006;331:214-218 (Pubitemid 43675523)
42. Genco A, Cipriano M, Bacci V, et al. BioEnterics intragastric balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes 2006;30:129-133 (Pubitemid 41790788)
43. Fernandes M, Atallah AN, Soares BG, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev 2007 . Published online 24 January 2007, doi:10.1002/14651858.CD004931.pub2
44. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Int Med 2005;143:380-85 •• Concise historical perspective on weight-loss therapeutics.
45. Hofbauer KG, Nicholson JR, Boss O. The obesity epidemic: current and future pharmacological treatments. Annu Rev Pharmacol Toxicol 2007;47:565-592 (Pubitemid 46272139)
46. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-77 (Pubitemid 46027230)
47. Drew BS, Dixon AF, Dixon JB. Obesity management: update on orlistat. Vasc Health Risk Manag 2007;3:817-821
48. Bray GA. Are non-prescription medications needed for weight control? Obesity 2008;16:509-514
49. Sharma B, Henderson DC. Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother 2008;9:2161-2173
50. Fillippatos TD, Derdemezis CS, Gazi IF, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008;31:53-65
51. Florentin M, Liberopoulos EN, Elisaff MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2008;9:378-387 (Pubitemid 351842191)
52. Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 2006;29:49-60 (Pubitemid 43780346)
53. Ryan DH. Use of sibutramine and other nonadrenergic and serotonergic drugs in the management of obesity. Endocrine 2000;13:193-199 (Pubitemid 30823373)
54. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005;4:1083-1095 (Pubitemid 41671605)
55. Raebel MA, Malone DC, Conner DA, et al. Health services use and health care costs of obese and nonobese individuals. Arch Intern Med 2004;164:2135-2140 (Pubitemid 39410803)
56. Runge CF. Economic consequences of the obese. Diabetes 2007;56:2668-2672 (Pubitemid 350063957)
57. Shen C, Sambamoorthi U, Rust G. Co-occurring mental illness and health care utilization and expenditures in adults with obesity and chronic physical illness. Dis Manag 2008;11:153-160 (Pubitemid 351871683)
58. Sullivan PW, Ghushchyan V, Wyatt HR, et al. Productivity costs associated with cardiometabolic risk factor clusters in the United States. Value Health 2007;10:443-450 (Pubitemid 350013264)
59. Padwal RS. Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004. Obes Res 2005;13:1905-1908
60. Srishanmuganathan J, Patel H, Car J, et al. National trends in the use and costs of anti-obesity medications in England 1998-2005. J Public Health 2007;29:199-202
61. Datamonitor. Commercial and pipeline perspectives: obesity. Datamonitor Report dhmc2236. 2006. Available from: http://www.datamonitor.com/Products/Free/ report?DHMC2236/020DMHC2236.html
62. Driscoll P. Obesity management products segment sales growth. MedMarket Diligence, LLC report #S825. 2007. Available from: http://mediligence.com/blog/ category/obesity
63. Cowen and Company. Therapeutic Categories Outlook. New York: Cowen & Co.; 2008
64. Rumsfeld JS, Nallamothu BK. The hope and fear of rimonabant. JAMA 2008;99:1601-1602
65. Sanofi-Aventis. Sanofi-Aventis is complying with the EMEA's recommendation to temporarily suspend the marketing authorization of Acomplia® in obese and overweight patients. 2008. Available from: www.sanofi-aventis.com
66. Sanofi-Aventis. Sanofi-Aventis to discontinue all clinical trials with rimonabant. 2008. Available from: www.sanofi-aventis.com
67. Fulmer T. Not cutting the fat. BioCentury 2008;16:A9-10
68. Merck. Merck discontinues development of investigational medicine taranabant for obesity. 2008. Available from: http://www.merck.com/newsroom/ press-releases/research-and-development/2008-1002.html
69. Pfizer. Pfizer discontinues development program for its phase 3 obesity compound (CP-945-598). 2008. Available from: http://mediaroom.pfizer.com/news/ Pfizer/20081105006339/en
70. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nature Rev Drug Discov 2008;7:961-962
71. Stern JS, Kazaks A, Downey M. Future and implications of reimbursement for obesity treatment. J Am Diet Assoc 2005;105:S104-9 (Pubitemid 40615763)
72. Bellocchio L, Cervino C, Pasquali R, et al. The endocannabinoid system and energy metabolism. J Neuroendocrinol 2008;20:850-857 (Pubitemid 351863320)
73. Matias I, Cristino L, Di Marzo V. Endocannabinoids: some like it fat (and sweet too). J Neuroendocrinol 2008;20 (Suppl 1):100-109 (Pubitemid 351552684)
74. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008;51:1356-1367
75. Engeli S. Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol 2008;20 (Suppl 1):110-115 (Pubitemid 351559284)
76. Kunos G, Osei-Hyiaman D, Liu J, et al. Endocannabinoids and the control of energy homeostasis. J Biol Chem 2008;283:33021-33025
77. Wang J, Ueda N. Role of the endocannabinoid system in metabolic control. Curr Opin Nephrol Hypertens 2008;17:1-10 (Pubitemid 350295190)
78. Jesudason D, Wittert G. Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol 2008;19:344-348
79. Perkins JM, Davis SN. Endocannabinoid system overactivity and the metabolic syndrome: Prospects for treatment. Curr Diab Rep 2008;8:12-19
80. Nogueiras R, Rohner-Jeanrenaud F, Woods SC, et al. The endocannabinoid system and the control of glucose homeostasis. J Neuroendocrinol 2008;20 (Suppl 1):147-151 (Pubitemid 351552686)
81. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-825 (Pubitemid 32303781)
82. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305 (Pubitemid 40629049)
83. D'Eton TM, Pierce KA, Roix JJ, et al. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008;57:1262-1268
84. Wilner LS, Arnold RM. Cannabinoids in the treatment of symptoms in cancer and AIDS. J Palliat Med 2006;9:802-804 (Pubitemid 43938857)
85. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-3180 (Pubitemid 44271774)
86. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73-100 (Pubitemid 43228239)
87. Duffy D, Rader D. Endocannabinoid antagonism: Blocking the excess in the treatment of high-risk abdominal obesity. Trends Cardiovasc Med 2007;17:35-43 (Pubitemid 46210169)
88. Blüher M, Engeli S, Klöting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006;55:3053-3060 (Pubitemid 44923642)
89. Côté M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes 2007;31:692-699 (Pubitemid 46482358)
90. Matias I, Petrosoino S, Racioppi A, et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol 2008;286 (Suppl 1):S66-78
91. Starowicz KM, Cristino L, Matias I, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity 2008;16:553-565 (Pubitemid 351328005)
92. Di Marzo V, Côté M, Matias I, et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009;52 (2):213-217
93. Benzinou M, Chevre JC, Ward KJ, et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum Mol Genet 2008;17:1916-1921 (Pubitemid 351865840)
94. Wright SM, Dikkers C, Aronne LJ. Rimonabant: new data and emerging experience. Curr Atheroscler Rep 2008;10:71-78
95. Nogueiras R, Veyrat-Durebex C, Suchanek PM, et al. Peripheral, but not central, CB1 antagonism provides food intake independent metabolic benefits in diet-induced obese rats. Diabetes 2008;57:2977-2991
96. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118:3160-3169
97. Greasley PJ, Clapham JC. Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing? Eur J Pharmacol 2006;553:1-9 •• Classic discussion of pharmacological modes of G protein modulation by ligands.
98. Bond RA, Ijzerman AP. Recent developments in constitutive receptor activity and inverse agonist, and their potential for GPCR drug discovery. Trends Pharmacol Sci 2006;27:92-96 (Pubitemid 43184030)
99. Canals M, Milligan G. Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed mu opioid receptors. J Biol Chem 2008;283:11424-11434
100. Leterrier C, Lainé J, Darmon M, et al. Constutitive activation drives compartment-selective endocytosis and axonal targeting of type 1 cannabinoid receptors. J Neurosci 2006;26:3141-3153
101. Neuman-Tancredi A, Audinot V, Moreira C, et al. Inverse agonism and constitutive activity as functional correlates of serotonin h5-HT1B receptor/G-protein stoichiometry. Mol Pharmacol 2000;58:1042-1049 (Pubitemid 30800795)
102. Wurch T, Pauwels PJ. Analytical pharmacology of G protein-coupled receptors by stoichiometric expression of the receptor and Go protein subunits. J Pharmacol Toxicol Meth 2001;45:3-16 (Pubitemid 32728217)
103. Yao BB, Mukherjee S, Fan Y, et al. In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 2006;149:145-154
104. Henness S, Robinson DM, Lyseng-Williamson KA. Rimonabant. Drugs 2006;66:2109-2119
105. Bifulco M, Grimaldi C, Gazzerro P, et al. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 2007;71:1445-1456 (Pubitemid 47010897)
106. Xie S, Furjanic MA, Ferrara JJ, et al. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use. J Clin Pharm Ther 2007;32:209-231 (Pubitemid 46699514)
107. Landsman RS, Burkey TH, Consroe P, et al. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 1997;334:R1-2 (Pubitemid 27417820)
108. Ward SJ, Dykstra LA. The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 2005;16:381-388
109. Bergman J, Delatte MS, Paronis CA, et al. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav 2008;93:666-670
110. Kintscher U. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and Stradivarius. Eur Heart J 2008;29:1709-1710 (Pubitemid 352019818)
111. Patel PN, Pathak R. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm 2007;64:481-489 (Pubitemid 46339261)
112. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134 (Pubitemid 41653104)
113. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397 (Pubitemid 40523733)
114. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-775 (Pubitemid 43244304)
115. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-1672 (Pubitemid 46048528)
116. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706-1713 (Pubitemid 350100788)
117. Scheen AJ, Van Gaal LF. Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes. Rev Med Liege 2007;62:81-85
118. Van Gaal L, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the rimonabant in obesity (RIO) program. Diabetes Care 2008;31:S229-40
119. Van Gaal LF, Scheen AJ, Rissanen AM, et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe study. Eur Heart J 2008;29:1761-1771 (Pubitemid 352019811)
120. Ruilope LM, Despres JP, Scheen A, et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens 2008;26:357-367
121. Rosenstock J, Hollander P, Chevalier S, et al. The SERENADE trial: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008;31:2169-2176
122. Despres JP, Ross R, Boka G, et al. Rimonabant reduces both intra-abdominal adiposity and liver fat and improves cardiometabolic risk factors: the ADAGIO-LIPIDS trial. The 77th European Atherosclerosis Society Congress, Istanbul, Turkey, April 26-29 2008
123. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299:1547-1560
124. Muccioli GG. Blocking the cannabinoid recpetors: drug candidates andtherapeutic promises. Chem Biodivers 2007;4:1805-1827 (Pubitemid 47377204)
125. Jagerovic N, Fernandez-Fernandez C, Goya P. CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr Top Med Chem 2008;8:205-230 (Pubitemid 351795770)
126. Fremming BA, Boyd ST. Taranabant, a novel cannabinoid type 1 receptor inverse agonist. Curr Opin Investig Drugs 2008;9:1116-1129
127. Hagmann WK. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. Arch Pharm Chem Life Sci 2008;341:405-411
128. Addy C, Li S, Agrawal N, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J Clin Pharmacol 2008;48:418-427
129. Addy C, Rothenberg P, Li S, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. J Clin Pharmacol 2008;48:734-744 (Pubitemid 351713158)
130. Addy C, Wright H, Van Laere K, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008;7:68-78
131. A multicenter study to evaluate the efficacy and safety of four doses of SR147778 in obese patients. 2004. Available from: http://wwwclinicaltrials.gov/ ct2/show/NCT00239174
132. Multiple-dose study to evaluate the efficacy, safety and pharmacokinetics of BMS-646256 in obese subjects. 2006. Available from: http:// wwwclinicaltrials.gov/ct/show/NCT0038609
133. Srivastava BK, Soni R, Joharapurkar A, et al. Bioisosteric replacement of dihydropyrazole of 4s-(-)-3-(4-chlorophenyl)-n-methyl-n′-[(4- chlorophenyl)-sulfonyl]-4-phenyl-4,5-di hydro-1h-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole. Bioorg Med Chem Lett 2008;18:963-968
134. BMS-646256 in obese and overweight type 2 diabetics. 2007. Available from: http://wwwclinicaltrials.gov/ct/show/NCT00541567
135. Herling AW, Gossel M, Haschke G, et al. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 2007;293:E826-E32 (Pubitemid 47358996)
136. Dose-ranging study evaluating AVE1625 in abdominally obese patients with atherogenic dyslipidemia. 2006. Available from: http://wwwclinicaltrials.gov/ct/ show/NCT00345410
137. Activity of AVE1625 in mild to moderate Alzheimer's patients. 2006. Available from: http://wwwclinicaltrials.gov/ct/show/NCT00380302
138. Efficacy and safety of AVE1625 as co-treatment with antipsychotic therapy in schizophrenia (CONNECT). 2007. Available from: http://wwwclinicaltrials.gov/ ct/show/NCT00439634
139. A study of 6-month duration to evaluate the weight loss effect of various doses of CP-945,598 in obese subjects. 2005. Available from: http://wwwclinicaltrials.gov/ct/show/NCT00134199
140. A long-term study to examine the effects of CP-945,598 on weight loss and safety. 2006. Available from: http://wwwclinicaltrials.gov/ct/show/NCT00375401
141. A 1-year study on the effects of CP-945,598 for the treatment of obesity in overweight type 2 diabetic patients. 2006. Available from: http://wwwclinicaltrials.gov/ct/show/NCT00391196
142. Effect of 2-year administration of CP-945,598 on weight loss efficacy and safety. 2007. Available from: http://wwwclinicaltrials.gov/ct/show/NCT00396448
143. A 14-month study on the effects of CP-945,598 for the prevention of weight regain in obese patients. 2008. Available from: http://wwwclinicaltrials. gov/ct/show/NCT00483171
144. Esteve. EP-01944293. Described in: Curr Opin Drug Discov Devel 2008;11:591-598
145. Safety and efficacy of low doses of V24343 in obese subjects. 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00734201
146. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: what fits whom? Diabetes Care 2008;31:S269-77
147. Rimonabant regulatory update in the United States. Sanofi-Aventis, 2007. Available from: http://en.sanofi-aventis.com/Images/070629-rimonabant-US-en- tem24-17003.pdf
148. Sanofi-Aventis received from the FDA an approvable letter for rimonabant for weight management and a nonapprovable letter for smoking cessation. 2006. Available from: http://www.sanofi-aventis.us/live/us/medias/7B804B87-CB40-4690- AD95-7880055B20A9.pdf
149. European Medicines Agency recommends Acomplia must not be used in patients on antidepressants or with major depression. EMEA, 2007. Available from: http://wwwemeaeuropaeuhumandocs/PDFs/EPAR/acomplia/32982607enpdf 2007
150. Soyka M, Koller G, Schmidt P, et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence. Results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 2008;28:317-324
151. Le Foll B, Forget B, Aubin HJ, et al. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 2008;13:239-252 (Pubitemid 351692986)
152. Doggrell SA. Is rimonabant efficacious and safe in the treatment of obesity? Expert Opin Pharmacother 2008;9:2727-2731
153. Gantz I, Erondu N, Suryawanshi S, et al. A two-year study to assess the efficacy, safety, and tolerability of taranabat in obese patients: 52 week results. American College of Cardiology Annual Scientific Session, Chicago, Illinois, USA, 29 March - 1 April 2008
154. Akbas F, Gasteyger C, Sjodin A, et al. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Revs 2009;10:58-67
155. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7:438-55 • Concise overview of advanced compounds for endocannabinoid-system pharmacotherapeutic modulation.
156. Lafenêtre P, Chaouloff F, Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol Res 2007;56:367-381 (Pubitemid 350026395)
157. Atherosclerosis underlying development assessed by intima-media thickness in patients on rimonabant (Auditor) 2005. Available from: http:// wwwclinicaltrials.gov/ct/show/NCT00228176
158. STRADIVARIUS (strategy to reduce atherosclerosis development involving administration of rimonabant - the intravascular ultrasound study). 2005. Available from: http://wwwclinicaltrials.gov/ct/show/NCT00124332
159. Study evaluating rimonabant efficacy in drug-naïve diabetic patients (SERENADE). 2005. Available from: http://wwwclinicaltrials.gov/ct/show/ NCT00257257
160. An international study of rimonabant in dyslipidemia with atherogenic risk in abdominally obese patients (ADAGIO-lipids). 2005. Available from: http://wwwclinicaltrials.gov/ct/show/NCT00239967
161. Comprehensive rimonabant evaluation study of cardiovascular endpoints and outcomes (CRESCENDO). 2005. Available from: http://wwwclinicaltrials.gov/ct/ show/NCT00263042
162. Study evaluating rimonabant efficacy in insulin-treated diabetic patients (ARPEGGIO). 2006. Available from: http://wwwclinicaltrials.gov/ct/show/ NCT00288236
163. Visceral fat reduction assessed by CT-scan on rimonabant (VICTORIA). 2006. Available from: http://wwwclinicaltrials.gov/ct/show/NCT00299325
164. Rimonabant in prediabetic subjects to delay onset of type 2 diabetes (RAPSODI). 2006 . Available from: http://wwwclinicaltrials.gov/ct/show/ NCT00325650
165. Pacher P, Mukhopadhyay P, Mohanraj R, et al. Modulation of the endocannabinoid system in cardiovascular disease. Therapeutic potential and limitations. Hypertension 2008;52:601-607
166. Viveros MP, Roderiguez de Fonseca F, Bermudez-Silva FJ, et al. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets 2008;8:220-230
167. Rimonabant to reduce alcohol consumption. 2003. Available from: http://wwwclinicaltrials.gov/ct/show/NCT00075205
168. Kunos G, Osei-Hyiaman D, Bátkai S, et al. 2008. Should peripheral
169. Pavón FJ, Serrano A, Pérez-Valero V, et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 2008; 20 (Suppl 1):116-123 (Pubitemid 351552685)
170. Chen RZ, Frassetto A, Lao JZ, et al. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Eur J Pharmacol 2008;584:338-342
171. Sink KS, McLaughlin PJ, Wood JA, et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008;33:946-955 (Pubitemid 351252707)
172. Gardner A, Mallet PE. Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur J Pharmacol 2006;530:103-106
173. Järbe TU, Lemay BJ, Olszewska T, et al. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats. Pharmacol Biochem Behav 2008;91:84-90
174. Salamone JD, McLaughlin PJ, Sink K, et al. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 2007;91:383-8 • Discussion of the in vivo and therapeutic implications of CB1 receptor-neutral antagonists on feeding. (Pubitemid 47016540)
175. Chambers AP, Vemuri VK, Peng Y, et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 2007;293:R2185-R93 (Pubitemid 350224010)
176. McLaughlin PJ, Winston K, Swezey L, et al. The cannabinoid CB1 antagonists SR141716a and AM251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003;14:583-588
177. Parker LA, Mechoulam R, Schlievert C, et al. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 2003;166:156-162 (Pubitemid 36313122)
178. McLaughlin PJ, Winston KM, Limebeer CL, et al. The cannabinoid CB1 antagonist AM251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology 2005;180:286-293 (Pubitemid 40909674)
179. Parker LA, Limebeer CL. Conditioned gaping in rats: a selective measure of nausea. Auton Neurosci 2006;129:36-41 (Pubitemid 44470862)
180. Sink KS,Vemuri VK, Wood J, et al. Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav 2009;91:303-306
181. Cheng Y, Hitchcock SA. Targeting endocannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Invest Drugs 2007;16:951-965 (Pubitemid 47074154)
182. Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol 2007;5:73-80 (Pubitemid 47019422)
183. Food and Drug Administration. FDA expands warning to consumers about tainted weight loss pills. January 8, 2009. Available at: 〈http://www.fda. gov/bbs/topics/NEWS/2008/NEW01933.html〉.